Adimmune Corporation (4142.TW)

TWD 19.3

(-2.28%)

Market Cap (In TWD)

8.13 Billion

Revenue (In TWD)

1.78 Billion

Net Income (In TWD)

-639.89 Million

Avg. Volume

1 Million

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
19.15-33.75
PE
-
EPS
-
Beta Value
0.459
ISIN
TW0004142005
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Chi-Hsien Chan
Employee Count
-
Website
https://www.adimmune.com.tw
Ipo Date
2012-05-03
Details
Adimmune Corporation manufactures and sells human vaccines in Taiwan. It offers AdimFlu-S, a quadrivalent influenza vaccine; tetanus toxoid alum precipitated product that is used for the prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent influenza vaccines; Quadrivalent influenza vaccine; Influenza A (H1N1) Virus Monovalent Vaccine; Tetanus Toxoid; and purified Tuberculin, as well as contract manufacturing services. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was founded in 1965 and is headquartered in Taichung, Taiwan.